Salivary glands are highly attractive targets for AAV-mediated gene therapy because they are encapsulated, easily accessible via the mouth, and can act as “bio-reactors” to secrete therapeutic proteins into both the saliva (for local oral/esophageal issues) and the bloodstream (for systemic diseases like diabetes or growth hormone deficiency).

Quick Legend: Administration Routes

• Retrograde Cannulation: The primary clinical route. A small catheter is inserted into the main salivary duct (e.g., Stensen’s duct for the parotid) through the mouth. The vector is infused “backwards” into the gland.
• Intraparenchymal (Direct): Direct needle injection into the gland tissue. More invasive and can cause localized tissue damage or uneven distribution.
• Systemic (IV): Generally inefficient for salivary glands due to the high “liver sink” and the protected nature of the glandular tissue.

---

1. Natural AAV Serotypes

Serotype	Primary Target Cells	Preferred Route	Key Characteristics & Notes
AAV5	Ductal & Acinar Cells	Retrograde	The Rodent Gold Standard. • Uses PDGFR (Platelet-Derived Growth Factor Receptor) for entry. • Shows significantly higher (5–10x) transduction efficiency than AAV2 in mice. • Note: Interestingly, efficiency is much lower in non-human primates (NHPs).
AAV2	Ductal Cells (Striated/Intercalated)	Retrograde	The Clinical Benchmark. • The most extensively studied in humans (e.g., for Sjögren’s syndrome and radiation-induced xerostomia). • Uses HSPG (Heparan Sulfate Proteoglycan) as a receptor. • Provides stable, long-term expression in primates (>6 months).
AAV9	Ductal Cells, Stroma	Retrograde	High Spread. • Highly efficient in rodents, similar to AAV5. • Known for its ability to escape the gland and enter the systemic circulation better than AAV2, which is useful if the goal is systemic protein delivery.
AAV4	Ductal Cells (including Excretory)	Retrograde	Broad Ductal Tropism. • Transduces a wider variety of ductal segments (convoluted granular tubules) compared to AAV2/5. • Uses O-linked sialic acid for cell entry.
AAVRh10	Acinar Cells	Retrograde	The Acinar Specialist. • One of the few serotypes that shows strong tropism for acinar cells (the cells that actually produce saliva) in rats and mice. • Superior to AAV2 in some NHP models.

---

2. Engineered & Specialized Capsids

These are often selected for their ability to target the secretory acinar cells or to function better in human tissue than standard rodent-optimized serotypes.

Variant	Primary Target Cells	Preferred Route	Key Characteristics & Notes
AAV44.9	Acinar Cells (Parotid/Sublingual)	Retrograde	Novel Secretion Tool. • A newer isolate found to be highly effective at transducing acinar cells. • Results in robust secretion of the transgene product into both saliva and blood.
AAV12	Salivary Epithelium	Retrograde	Antibody Evader. • Does not require sialic acid or heparin for entry. • Uniquely resistant to the neutralizing antibodies (NAbs) commonly found in human serum, making it a “cleaner” clinical candidate.
AAV-DJ	Broad Epithelium	Retrograde	High Output. • A synthetic hybrid that provides extremely high levels of protein production in salivary cells in vitro and in rodent models.

---

3. Tropism by Application

If you are choosing a vector for a specific salivary application:

• Repairing Dry Mouth (Radiation/Sjögren’s): AAV2 (human trials) or AAVRh10 (to target acinar cells).
• Systemic Protein Delivery (e.g., Insulin, EPO): AAV5 or AAV9 (highest yield in rodent models).
• Local Oral Therapy (e.g., Histatin for fungal infections): AAV2 (stays localized in the gland well).
• Treating Obesity/Metabolism (e.g., PYY, GLP-1): AAV5 (widely used in experimental taste/metabolism studies).

Critical Factor: The Ductal vs. Acinar Divide

Most natural AAVs (especially AAV2) have a “Ductal Tropism.”

1. The Limitation: If you only transduce ductal cells, you can’t easily fix a saliva production problem because ductal cells mostly modify saliva rather than create it.
2. The Solution: For “Water-Flux” restoration (fixing dry mouth), you need to target Acinar cells (which create the fluid) or deliver a gene like AQP1 (Aquaporin-1) to ductal cells to turn them into water-conducting cells. AAVRh10 and AAV44.9 are currently the best candidates for direct acinar targeting.